Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

• Type of Material: Article
• Authors: Xiaofei Zhou, Takeda Development Center Americas, Inc.; Ulka Vaishampayan, Karmanos Cancer Institute; Devalingam Mahalingam, Northwestern Medical Group; R Donald Harvey, Emory University; Ki Young Chung, Prisma Health Cancer Institute; Farhad Sedarati, Takeda Development Center Americas, Inc.; Cassie Dong, Takeda Development Center Americas, Inc.; Douglas Faller, Takeda Development Center Americas, Inc.; Karthik Venkatakrishnan, Takeda Development Center Americas, Inc.; Neeraj Gupta, Takeda Development Center Americas, Inc.
• Language: English
• Date: 2022-08-06
• Publisher: SPRINGER
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2022
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1007/s10637-022-01286-8
• Title of Journal or Parent Work: INVESTIGATIONAL NEW DRUGS
• Volume: 40
• Issue: 5
• Start Page: 1042
• End Page: 1050
• Grant/Funding Information: This study was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
• Keywords: Science & Technology; LYMPHOMA; Oncology; Pharmacokinetics [4 to 6 max]; Rifampin; PROTEIN NEDDYLATION; Pharmacology & Pharmacy; Pevonedistat; TAK-924/MLN4924; Life Sciences & Biomedicine; Advanced malignancies
• Research Categories: Chemistry, Pharmaceutical; Health Sciences, Oncology

Abstract

Summary: Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase 1 study evaluating the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics (PK) of pevonedistat in patients with advanced solid tumors (NCT03486314). Patients received a single 50 mg/m2 pevonedistat dose via a 1-h infusion on Days 1 (in the absence of rifampin) and 10 (in the presence of rifampin), and daily oral dosing of rifampin 600 mg on Days 3–11. Twenty patients were enrolled and were evaluable for PK and safety. Following a single dose of pevonedistat at 50 mg/m2, the mean terminal half-life of pevonedistat was 5.7 and 7.4 h in the presence and in the absence of rifampin, respectively. The geometric mean AUC0–inf of pevonedistat in the presence of rifampin was 79% of that without rifampin (90% CI: 69.2%–90.2%). The geometric mean Cmax of pevonedistat in the presence of rifampin was similar to that in the absence of rifampin (96.2%; 90% CI: 79.2%–117%). Coadministration of pevonedistat with rifampin, a strong metabolic enzyme inducer, did not result in clinically meaningful decreases in systemic exposures of pevonedistat. The study results support the recommendation that no pevonedistat dose adjustment is needed for patients receiving concomitant CYP3A inducers. ClinicalTrials.gov identifier: NCT03486314.